Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Biotech
Agomab's ALK5 inhibitor hits intestinal target in Crohn's trial
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.
James Waldron
Mar 10, 2025 8:50am
Sanofi shows how $500M IBD bet compares to Merck, Roche rivals
Feb 24, 2025 8:11am
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
Lilly inks $3.2B Morphic buyout to take on Takeda in IBD
Jul 8, 2024 8:20am
AbbVie pays $150M for preclinical IBD drug to join TL1A race
Jun 13, 2024 9:45am
